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Summary.-Spleen cells collected from mice bearing transplanted chemically induc-
ed syngeneic fibrosarcomas non-specifically inhibited DNA synthesis of sarcoma
and lymphoma target cells in vitro. Splenocytes from mice hyper-immunized against
a syngeneic sarcoma specifically inhibited DNA synthesis of the tumour used for
immunization. The impairment of tumour-cell DNA synthesis was associated in
vitro with cytostasis, and lysis of the target cells was not seen. Since treatment with
anti-0 serum and complement did not impair cytostatic action of the spleen cells,
and since thymus-deprived animals showed similar activity to normal mice, T
lymphocytes were not involved in non-specific cytostasis. Removal of phagocytic
adherent cells by carbonyl iron markedly inhibited the cytostatic activity of the
spleen cells, suggesting a role in this reaction for cells of the monocyte-macrophage
series. The presence of an actively growing sarcoma was a prerequisite for the
expression of non-specific cytostasis, since surgical excision resulted in complete
disappearance of this activity of spleen cells.
CELLULAR effector mechanisms detectable
in vitro during the growth ofexperimental
tumours are heterogeneous. T cells, B cells
and armed macrophages can express
specific cytotoxicity in vitro against svn-
geneic target cells (Plata et al., 16973;
Lamon et al., 1973; Evans and Alexander,
1970).
Moreover, in addition to the specific
effector mechanisms, non-specific cyto-
toxicity has been reported for lymph-
node cells in rats bearing a chemically
induced sarcoma (Currie and Gage, 1973)
and in spleen cells of mice bearing virus-
induced tumours (Kirchner, Holden and
Herbermann, 1975a; Seeger, Rayner and
Owen, 1974). In the present investigation
we have analysed the non-specific cell-
mediated inhibition of tumour cell DNA
synthesis detectable in vitro during the
growth of chemically induced fibro-
sarcomas transplanted intosyngeneic mice.
MATERIALS AND METHODS
Animals.-CBA, C57BL and DBA/2 mice
(8-10 weeks old) were used throughout.
Thymectomized, X-irradiated, bone-mar-
row-reconstituted (T-lymphocyte-deprived)
CBA mice were provided by Dr A. J. S.
Davies, and were prepared as previously
described (Davies et al., 1969). The absence of
a thymus was checked at autopsy on the
termination of the experiment.
Tumours.-The benzopyrene-induced FS6
and FS13 sarcomas were maintained by i.m.
inoculation of 106 cells in the hind limb of
syngeneic C57BL and CBA mice respectively.
The tumours do not metastasize spontane-
ously and they kill the mice in 25-30 days.
The SL2 and TLX9 lymphomas were main-
tained by i.p. passage in the syngeneic hosts,
DBA/2 and C57BL mice respectively. Unless
otherwise stated, mice (4-6 per experimental
group) were used 15-20 days after tumour
implantation. Surgical excision of the sar-
comas was performed by amputating the
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affected limb. The tumours were cultivated
in vitro in Medium RPMI 1640 contain-
ing 25 mm N-2-hydroxyethylpiperazine-N'-2-
ethanesulphonic acid (Gibco-Biocult, Glas-
gow, Scotland), 50 ,ug/m] streptomycin, 50
i.u./ml penicillin and 10% foetal bovine
serum (growth medium).
Spleen cells.-Spleens were minced with
scissors in Medium 199 (Wellcome Research
Laboratories, Beckenham, England). After
resuspension with a Pasteur pipette, the cells
were washed twice with Medium 199 and
finally resuspended in growth medium.
To kill T lymphocytes, spleen cells (107/ml)
were incubated for 45 min with 1: 8 diluted
AKR anti-6 serum (Searle) and 1: 10 diluted
rat or guinea-pig serum as a source ofcomple-
ment (Reif and Allen, 1964). The anti-0
serum employed for these studies killed
> 90% thymocytes, < 5% bone-marrow cells
and 25% splenocytes.
Phagocytic adherent cells were removed by
the carbonyl-iron method (Lundgren, Zukoski
and MolJer, 1968). After treatment with
carbonyl iron, the percentage of phagocytic
elements assessed by neutral-red uptake was
< 0500. Confirmation of their removal was
provided by demonstrating that C. parvum-
induced spleen macrophage cytotoxicity was
abolished by this procedure, in agreement
with previous reports (Kirchner, Holden and
Herbermann, 1975b).
125IUdR uptake assay.-5 x 104 Lym-
phoma cells were incubated for 48 h with
spleen cells in a final volume of 1-5 ml growth
medium in plastic tubes (Cat. No. 2058,
Falcon, Oxnard, California, U.S.A.). The
routinely employed effector: target cell
(E: T) ratio was 50: 1. Under these condi-
tions normal spleen cells did not affect DNA
synthesis of the tumour cells. Most of the
experiments presented were performed using
C57BL splenocytes and TLX9 tumour cells as
effector and target cells respectively. At the
end of the incubation, cells were spun down,
and washed at least twice with 2 ml of
Medium 199 before resuspension in 1 ml of
Medium 199 containing 041 ,uCi of 5-[1251]_
iodo-2'-deoxyuridine (125IUdR, Radiochemi-
cal Centre, Amersham, England). This wash-
ing procedure was critical to remove inhibi-
tors which compete with 125JUdR during
uptake by dividing cells (Evans and Booth,
1976).
After incubation for 4 h, acid-precipitable
radioactivity was determined in a well-type
y-counter as previously described (Boyle and
Ormerod, 1975).
125IUdR uptake by appropriate spleen cells
in the absence of tumour cellswas subtracted,
and percent inhibition of 125IUdR uptake
calculated according to the formula:
(1 - A x 100
where A is the radioactivity in the test group
and B is the radioactivity incorporated by
lymphoma cells in the absence of effector
cells. It should be noted that no significant
stimulation of DNA synthesis occurred when
2-5 x 106 C57BL spleen cells were incubated
for 48 h with 0-8 x 106 X-irradiated (5000
rad) lymphoma cells.
When fibrosarcoma cells were employed as
targets, 5 x 104 tumour cells were incubated
for 48 h w%rith splenocytes in Linbro plates
(FM 16-24, Linbro Chemical Co., New Haven,
Connecticut, U.S.A.). At the end of the
incubation, the cells w%ere incubated for
20 min at 37°C with 0.1% trypsin in Medium
199 (Evans, 1973), transferred to plastic
tubes, -Nashed and pulsed as described above.
125JUdR-release assay.-TLX9 lymphoma
cells were incubated for 16-20 h with 125IUdR
(0 003 ,tCi/105 cells/ml) in growth medium.
After washing twice with 25 ml of Medium
199, 5 x 104 tumour cells were incubated for
24 or 48 h with 5 x 106 spleen cells in 195 ml
of growth medium in plastic tubes. 125IUdR
release was calculated according to the
formula:
x 100
w"here a is the 125J in the supernatant and b is
the isotope present in the cell pellet.
Statistical analysis.-Results presented are
the mean of 3 replicates, and statistical
significance was assessed by Duncan's new
multiple-range test.
RESULTS
Spleen cells collected 2 weeks after the
implantation of the FS6 and FS13 fibro-
sarcomas inhibited non-specifically the
DNA synthesis of syngeneic and allo-
geneic sarcoma and lymphoma cells (Table
I). In preliminary experiments, similar
results were obtained with a third chemi-
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TABLE I.-Non-specific Inhibitiov
Synthesis of Tumour Cells b
Cells from Sarcoma-bearing Mi(
Spleen cells
obtained
from mice
bearing Target cells
F86 F86 sarcoma (C57BL)
(C57BL) FS9 sarcoma (CBA)
sarcoma FS13 sarcoma (CBA)
SL2 lymphoma (DBA/2)
TLX9 lymphoma (C57BL)
FS13 FS9 sarcoma (CBA)
(CBA) FS13 sarcoma (CBA)
sarcoma SL2 lymphoma (DBA/2)
TLX9 lymphoma (C57BL)
?,ofDANA TABLE III. Inhibition of DNA Synthesis
ty Spleen of TLX9 Lymphoma by Spleen Cells of
ce C57BL Mice Bearing the FS6 Sarcoma,
% Tested at Different Effector: Target Cell
inhibition Ratios (E: T)
of
25IIJdR
uptake
57
85
43
86
81
56
78
68
73
cally induced tumour, the CBA fibro-
sarcoma, FS9. Following surgical excision
of the FS6 sarcoma, C57BL mice were
able to reject a challenge with live FS6
tumour cells.
Splenocytes collected from these im-
mune mice showed specific cytotoxicity
for the FS6 tumour in the 125IUdR uptake
assay (Table II). Thus the lack of specifi-
city observed in mice bearing actively
growing tumours was not due to common
antigenic determinants shared by the
sarcomas and lymphomas used as targets
for these studies.
TLX9 lymphoma cells were employed
to characterize the non-specific inhibitory
effect on target-cell DNA synthesis ofFS6
TABLE II.- Specific Inhibition of DNAA
Synthesis ofTumour Cells by Spleen Cells
from C57BL Mice that had been Hyper-
immunized against the Syngeneic FS6
Sarcoma
Spleen O/ inhibition of 125IUdR uptake by
cells
obtained FS6 FS 13 SL2 TLX9
from sarcoma sarcoma lymphoma lymphoma
FS6- 44 43 75 66
bearing
mice
Immune
mice*
72 24 13 -8
* The F86 sarcoma was excised 2 weeks after
implantation, and 10 days later the animals were
injected with 5 x 105 tumour cells i.m. The second
inoculum was rejected and tests were performed
2 wveeks later.
Cultures
TLX9 cells alone
Normal spleen cells +
TLX9 cells
Tumour-bearing (14 (lays) +
TLX9 cells
125IUdR
uptake
E: T (ct/mir)
18086
100: 1 14649
50 1 18159
25 1 20339
100 1 2500
50:1 4323
25:1 8451
tumour-bearing spleen cells. As shown in
Table III, the degree of inhibition of
125IUdR uptake was related to the
number of effector cells employed in the
assay. As reported recently (Evans and
Booth, 1976) inhibition of tumour-cell
DNA synthesis does not necessarily imply
impairment of tumour-cell proliferative
capacity. Therefore, in one series of
experiments, lymphoma cells were counted
by use of a haemocytometer.
E
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Timeof culturewith spleencells(h)
FIG. 1. Inhibition of growth of TLX9
lymphoma cells (105 cells/ml) in vitro by
5 x 106 spleen cells/ml from normal
C57BL mice ( 0 ); and from C57BL
mice 14 days after s.c. implant ofsyngeneic
FS6 sarcoma ( ).
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As shown in Fig. 1, in the presence of
splenocytes from FS6 tumour-bearing
mice, actual inhibition of tumour growth
was observed.
When 125JUdR-prelabelled TLX9 lym-
phoma cellswere cultivated inthe presence
of spleen cells from tumour-bearing mice,
no significant degree of lysis could be
detected over a period of up to 48 h
(Table IV). On the other hand, in parallel
experiments marked inhibition of lym-
phoma DNA synthesis was observed, thus
suggesting that non-specific cytotoxicity
was the expression ofa cytostatic reaction,
and did not involve lysis of target cells.
The time course for the appearance ofnon-
specific cytostasis was determined in
TABLE IV.-Comparison of Inhibition of
DNA Synthesis and of Lysis of TLX9
Lymphoma Cells by Spleen Cells from
Mice Bearing FS6 Fibrosarcoma
Cultures
TLX9 cells alone
Normal spleen cells +
TLX9 cells
Tumour-bearing spleen
cells + TLX9 cells
a)
(0
CL
D
5l
% inhibition
of 125IUdR
uptake
24h 48h
15
73
-10
82
% 125IUdR
release
24h 48h
19
15
11
31
32
38
0k
Day after implantation of the FS6 fibrosarcoma
FIG. 2. Rate of development of cytostatic
activity of spleen cells of C57BL mice after
s.c. implantation ofsyngeneic FS6 sarcoma.
The effect ofsurgical removal ofthe tumour
at 7 and 14 days is shown.
C57BL mice transplanted with the FS6
tumour (Fig. 2). No significant cyto-
toxicity was detectable on Day 7, when
the tumour was just palpable and weighed
about 02 g, but marked inhibition of
TLX9 lymphoma DNA synthesis was
observed on Day 15, and this remained at
a constant level thereafter. Similar results
were obtained with the FS13 sarcoma
(Fig. 3). Surgical excision of the growing
w
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UAY AFTER F13 IUMUUH IMPLANATIIUN
FIG. 3. Rate of development of cytostatic
activity of spleen cells of CBA mice after
s.c. implantation of syngeneic FS13 sar-
coma. The effect is shown in both normal
CBA mice (*) and in CBA mice deficient in
T lymphocytes (0) due to adult thymec-
tomy and whole-body irradiation followed
by bone-marrow restitution.
sarcomas on Day 7 prevented the appear-
ance of non-specific cytostasis, while
surgery on Day 15 resulted in complete
disappearance of cytotoxicity by Day 30
(Figs 2 and 3).
In another series of experiments, the
nature of effector cells involved in this
non-specific cytotoxic reaction was investi-
gated. As illustrated in Fig. 3, T-lympho-
cyte-depleted CBA mice transplanted with
the FS13 fibrosarcoma showed cytotoxicity
levels similar to those displayed by normal
mice. Spleen cells obtained from non-
tumour-bearing T-cell-deprived CBA mice
did not inhibit target-cell DNA synthesis.
Treatment with anti-8 serum and comple-
38CYTOTOXIC SPLEEN CELLS IN MICE WITH TUMOURS 39
TABLE V.-Afect of Carbonyl Iron and
Anti-O Serum on the Non-specific Inhibi-
tion of DNVA Synthesis of the TLX9
Lymphoma by Spleen Cells from C57BL
Mice Bearing the FS6 Sarcoma
0/
,0
iiihibition
of
125IUdR
CUltures* Treatmenit uptaket
Normal spleen cells 3
CaIrboniyl Fe 10
Tumour-bearing spleen 86
cells Carbonyl Fe 44**
Normal spleein cells -1 5
Anti-6 + C' 5
Tuimour-bearinig spleen 71
cells Anti-0 + C' 85
* Cultuires were 5 x 1 04 TLX9 cells iiictubatedi
with 2-5 x 106 spleen cells in a total of 1-5 ml
cutlture medium.
** P < 0-01.
t Relative to uiptake by TLX9 cells alone.
ment didnotimpairnon-specific cytostasis,
whereas removal of phagocytic cells with
carbonyl iron markedly inhibited this
activity (Table V).
I)SCUSSION
The results )resented show that spleen
cells collected from mice bearing trans-
planted chemically induced sarcomas non-
specifically inhibited both the DNA syn-
thesis and growth of tumour cells in vitro.
They confirm and extend previous obser-
vations in rats bearing chemically induced
sarcomas (Currie and G-age, 1973) and in
mice bearing virus-induced tumours
(Seeger et al., 1974; Kirchner et al., 1975).
The non-specific cytostasis did not result
in a significant degree oflysis ofthe target
cells within 48 h. Since the TLX9 cells
employed for these experiments were
easily lysed by alloantibody and comple-
ment, or by alloimmune lymphocytes or
macrophages, the failure ofthe spleen cells
of tumour-bearers to cause lysis was not
due to an inherent resistance of these
lymphoma cells to lytic processes.
The non-specific cytotoxic activity of
spleen cells from tumour-bearers was
qualitatively different from that shown by
spleen cells from hyperimmunized mice,
since the latter was both specific and caus-
ed lysis. The effector cells responsible for
the non-specific cytostasis probably be-
longed to the mononuclear phagocytic
series, since T-lymphocyte-deprived mice
showed no impairment ofthis cytotoxicity,
and treatment with anti-6 serum and
complement did not reduce the cytostasis
of the spleen cells. Removal of phago-
cytic adherent cells by carbonyl iron
markedly reduced but did not abolish
cytotoxicity. The residual cytotoxicity
following treatment of the cells with
carbonyl iron might be due to macrophage
precursors which do not spread and adhere
rapidly (Meerpohl, Lohmann-Matthes and
Fischer, 1976).
Early surgical excision of the growing
sarcomas prevented the development of
non-specific cytostasis, and late removal of
the tumour caused this activity to dis-
appear. This finding, together with the
observation that hyperimmunized spleno-
cytes are specifically cytotoxic for the
tumour employed for immunization, sug-
gests that the presence of an actively
growing tumour is a prerequisite for the
expression of non-specific cytostasis.
Macrophages from immune mice can be
rendered non-specifically cytotoxic on the
addition of antigen, and normal macro-
phages may become cytotoxic on binding
immune complexes on their surface (Evans
and Alexander, 1976). A growing sar-
coma, causing a continuous presence of
circulating antigen or antigen-antibody
complexes (Thomson et al., 1973) could
provide the conditions for in vivo activa-
tion ofspleen macrophages.
This investigation was supported by a
programme grant from the Medical Re-
search Council. A. Mantovani was partially
supported by a British Council Fellow-
ship. We thank Mrs A. Pendry for per-
forming surgical excisions.
REFERENCES
BOYLE, M. D. P. & ORMEROD, M. G. (1975) The
Destruction of Tumour Cells by Alloimmune
Peritoneal Cells: Mechanism ofAction ofActivated40 A. MANTOVANI, R. EVANS AND P. ALEXANDER
Macrophages In vitro. J. Reticuloendothel. Soc., 17,
73.
CURRIE, G. A. & GAGE, J. 0. (1973) Influence of
Tumour Growth on the Evolution of Cytotoxic
Lymphoid Cells in Rats bearing a Spontaneously
Metastasizing Syngeneic Fibrosarcoma. Br. J.
Cancer, 28, 136.
DAVIES, A. J. S., CARTER, R. L., LEUCHARS, E. &
WALLIS, V. (1969) The Morphology of Immune
Reactions in Normal, Thymectomized and Re-
constituted Mice. II. The Response of Oxazolone.
Immunology, 17, 111.
EVANS, R. (1973) Macrophages and the Tumour-
bearing Host. Br. J. Cancer, 28, (Suppl. 1), 19.
EVANS, R. & ALEXANDER, P. (1970) Co-operation of
Immune Lymphoid Cells with Macrophages in
Tumour Immunity. Nature, Lond., 228, 620.
EVANS, R. & ALEXANDER, P. (1976) Mechanisms of
Extracellular Killing of Nucleated Mammalian
Cells by Macrophages. In: Immunobiology of the
Macrophage, Ed. D. S. Nelson. New York:
Academic Press. p. 535.
EVANS, R. & BOOTH, G. (1976) Inhibition of 125IUdR
Incorporation by Supernatants from Macrophage
and Lymphocyte Cultures: a Cautionary Note.
Cell. Immunol., 26, 120.
KIRCHNER, H., HOLDEN, H. T. & HERBERMANN,
R. B. (1975a) Inhibition of In vitro Growth of
Lymphoma Cells by Macrophages from Tumour
bearing Mice. J. natn. Cancer Inst., 55, 971.
KIRCHNER, H., HOLDEN, H. T. & HERBERMANN,
R. B. (1975b) Splenic Suppressor Macrophages
Induced in Mice by Injection of Corynebacterium
parvum. J. Immunol., 115, 1212.
LAMON, E. W., WIGZELL, H., ANDERSSON, B. &
KLEIN, E. (1973) Antitumor Activity In vitro
Depending on B Lymphocytes. Nature, New Biol.,
244, 209.
LUNDGREN, G., ZUKOSKI, C. F. & M6LLER, G. (1968)
Differential Effects of Human Granulocytes and
Lymphocytes on Human Fibroblasts in vitro. Clin.
exp. Immunol., 3, 817.
MEERPOHL, H. G., LOHMANN-M.ATTHES, M. L. &
FISCHER, H. (1976) Studies on the Activation of
Mouse Bone Marrow-derived Macrophages by the
Macrophage Cytotoxicity Factor (MCF). Eur. J.
Immunol., 6, 213.
PLATA, F., GOMARD, E., LECLERC, J. C. & LEVY, J. P.
(1973) Further Evidence for the Involvement of
Thymus-processed Lymphocytes in Syngeneic
Tumor Cell Cytolysis. J. Immunol., 111, 667.
REIF, A. E. & ALLEN, J. M. V. (1964) The AKR
Thymic Antigen and its Distribution in Leu-
kemias and Nervous Tissues. J. exp. Med., 120,
413.
SEEGER, R. C., RAYNER, S. A. & OWEN, J. T. (1974)
An Analysis of Variables Affecting the Measure-
ment of Tumor Immunity in vitro with 125k-
iododeoxy-uridine-labelled Target Cells. Studies
of Immunity to Primary Moloney Sarcomas. Int.
J. Cancer, 13, 697.
THoMsoN, M. D. P., SELLENS, V., ECCLES, S. &
ALEXANDER, P. (1973) Radioimmunoassay of
Tumour specific Transplantation Antigen of a
Chemically Induced Rat Sarcoma: Circulating
Soluble Tumour Antigen in Tumour Bearers. Br.
J. Cancer, 28, 377.